Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00431067
What this trial is testing

Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Ended earlyNCT04720664
What this trial is testing

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerHormone Receptor Positive Breast Carcinoma
Georgetown University 11
Testing effectiveness (Phase 2)UnknownNCT03993964
What this trial is testing

Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Sun Yat-sen University 20
Testing effectiveness (Phase 2)UnknownNCT04571437
What this trial is testing

Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast CancerMetastatic Breast Cancer
Cairo University 204
Testing effectiveness (Phase 2)Active Not RecruitingNCT03125928
What this trial is testing

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Fox Chase Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT03417544
What this trial is testing

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Who this might be right for
HER2-positive Metastatic Breast CancerCentral Nervous System Metastases
Nancy Lin, MD 19
Large-scale testing (Phase 3)Looking for participantsNCT06435429
What this trial is testing

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Who this might be right for
Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals 550
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Testing effectiveness (Phase 2)UnknownNCT03750396
What this trial is testing

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Who this might be right for
Breast CancerRecurrent Breast CancerStereotactic Body Radiotherapy+3 more
Gangnam Severance Hospital 110
Testing effectiveness (Phase 2)Study completedNCT03755141
What this trial is testing

Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
National Cancer Center, Korea 109
Large-scale testing (Phase 3)Active Not RecruitingNCT05077449
What this trial is testing

XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 300
Early research (Phase 1)Active Not RecruitingNCT02792114
What this trial is testing

T-Cell Therapy for Advanced Breast Cancer

Who this might be right for
Breast CancerMetastatic HER2-negative Breast
Memorial Sloan Kettering Cancer Center 186
Large-scale testing (Phase 3)UnknownNCT00430001
What this trial is testing

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Danish Breast Cancer Cooperative Group 300
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Testing effectiveness (Phase 2)Study completedNCT01441947
What this trial is testing

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 68
Testing effectiveness (Phase 2)UnknownNCT05025735
What this trial is testing

Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-negative Breast Cancer
Saint Luke's Health System 25
Early research (Phase 1)Study completedNCT04253561
What this trial is testing

Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT04448886
What this trial is testing

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

Who this might be right for
Invasive Breast CancerMetastatic Breast CancerHR-Positive Breast Cancer+1 more
Ana C Garrido-Castro, MD 110
Testing effectiveness (Phase 2)Looking for participantsNCT07510802
What this trial is testing

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Who this might be right for
Breast Cancer (Advanced/Metastatic)HER2-positive Breast CancerTriple-negative Breast Cancer
Beijing Biotech 60
Testing effectiveness (Phase 2)Study completedNCT01491737
What this trial is testing

Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 258
Next Page